Compare RRX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRX | TGTX |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.5B |
| IPO Year | 1994 | 2008 |
| Metric | RRX | TGTX |
|---|---|---|
| Price | $175.86 | $64.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $232.20 | $77.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | 42.86 | ★ 1746.67 |
| EPS | ★ 2.52 | 0.52 |
| Revenue | ★ $3,257,100,000.00 | $2,785,000.00 |
| Revenue This Year | $4.75 | $61.95 |
| Revenue Next Year | $12.95 | $35.55 |
| P/E Ratio | ★ $71.67 | $124.76 |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $127.96 | $26.76 |
| 52 Week High | $247.80 | $68.03 |
| Indicator | RRX | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 64.72 |
| Support Level | $148.19 | $51.70 |
| Resistance Level | $221.59 | N/A |
| Average True Range (ATR) | 9.12 | 3.49 |
| MACD | 1.81 | 0.65 |
| Stochastic Oscillator | 64.06 | 73.78 |
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.